MURATA-MANUFACTURING
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) is expanding its range of multilayer ceramic capacitors (MLCC) with the groundbreaking new GRM188C80E107M and GRM188R60E107M. Designed to cater to the continuous demands for miniaturization in servers, data centers, and IT applications, this solution stands out as the world’s first MLCC to provide a capacitance of 100μF in a 0603-inch (1608mm) size package.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724225305/en/
[Murata Manufacturing Co., Ltd.] The new MLCC, GRM188C80E107M and GRM188R60E107M (Photo: Business Wire)
In a wide array of consumer, IT, and industrial electronic devices, Murata’s MLCCs are utilized as a pivotal component that serves the purpose of temporarily storing and discharging electricity, dampening noise in signals, extracting signals at specific frequencies, as well as blocking direct current while permitting the flow of alternating current. With its compact packaging, 2.5V rated, low equivalent series resistance (ESR) and impedance, and X6S/X5R temperature classes, the new GRM188 is ideal for decoupling and smoothing circuits in demanding computer and network environments.
Within server and data centers, there is a continuous push to increase miniaturization and increase efficiency, while reducing material consumption. As performance and integration are advanced, the need for components to occupy less space and withstand higher temperatures becomes crucial. The impetus behind these industry advancements is further propelled by the demand for enhanced AI capabilities.
Leveraging Murata’s thin layer forming technology and a high-precision lamination process to meet the needs of the industry, the new GRM188 provides a wide operating temperature range and is the first 100μF MLCC capacitor available in 0603 packaging. It enables designers to further push system miniaturization by decreasing the number of capacitors used, allowing for a simultaneous reduction in circuit substrate area.
“The GRM188 represents yet another world-first achievement for Murata’s MLCC lineup, surpassing previous limitations and aligning perfectly with market demands,” said Hidetoshi Nakagawa, General Manager of Ceramic Capacitor Marketing at Murata. “In addition, this miniaturization not only improves the design of end applications and reduces the number of materials needed, but it also decreases electricity consumption during manufacturing, providing a dual benefit for sustainability.”
The 2.5V rated GRM188C80E107M products with a -55°C to 105°C temperature range and the 2.5V rated GRM188R60E107M products with a -55°C to 85°C temperature range are already in production with samples available for evaluation. Also, the new GRM188 with a rated voltage of 4.0V at -55°C to 85°C goes into mass production in 2025. Please contact us for details: contact form
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724225305/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom